Results 111 to 120 of about 76,993 (146)

Integrative multi-omics analysis identifies AEBP1 and EFEMP2 as key regulators of immune heterogeneity and therapeutic response in glioblastoma. [PDF]

Discov Oncol
Yin Y, Fu X, Gong S, Xie Y, Wu W, Li Z, Wu S, Gao Z, Hu K, Luo C, Wang H.   +10 more
europepmc   +1 more source

Switching Roles─Exploring Concentration-Dependent Agonistic versus Antagonistic Behavior of Integrin Ligands. [PDF]

J Med Chem
Ludwig BS, Krautkremer N, Tomassi S, Di Maro S, Di Leva FS, Benge A, Nieberler M, Kessler H, Marinelli L, Kossatz S, Reuning U.   +10 more
europepmc   +1 more source

Plan for increased Africa States EDCTP memberships M21

Engagement with the African Member states for enhanced GH EDCTP3 ...
openaire   +1 more source

Targeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide. [PDF]

Sci Rep
Lingasamy P, Tobi A, Kurm K, Tammik O, Teesalu T.   +4 more
europepmc   +1 more source

D5.5 EBRAINS modeling workflows implementation status at M21

M21 status on installed workflows and simulation engines including tools interconnected according to EBRAINS architecture specification, closed-loop simulation solutions, and new release of tools interconnected by EBRAINS APIs.
openaire   +1 more source

Societies at risk: the association between conflict intensity and population health indicators in Venezuela. [PDF]

Popul Health Metr
Olson E, Alhaffar MBA, Eriksson A.
europepmc   +1 more source

cross-DIH and Regions-Europe Experimentations Report M21

This report includes the achievements and lessons learned from the cross-DIH experiments to be also shared with AI4EU ...
openaire   +1 more source

Design, synthesis and biological evaluation of <i>N</i>-pyridinyl ureidobenzenesulfonates and their hydrochloride salts as novel water-soluble dihydroorotate dehydrogenase inhibitors inducing differentiation of acute myeloid leukemia cells. [PDF]

RSC Med Chem
Ouellette V, Bouzriba C, Chavez Alvarez AC, Hamel-Côté G, Fortin S.   +4 more
europepmc   +1 more source

City4Age frailty and MCI risk model, v2 (M21)

Starting from the needs and unmet needs of the elderly population represented by the 6 Test Beds, this task will define a model of risks for frailty and MCI that will be the basic scientific rationale for the City4Age approach and the guidance in designing the approach to the problem and the interventions.
openaire   +1 more source